SmartBreast Corp logo — MBI Saves Lives through Early Cancer Detection in Dense Brea...

SmartBreast Corp

MBI Saves Lives through Early Cancer Detection in Dense Breasts

Founded 2019 United States United States 5 employees

General Information

Company Name SmartBreast Corp
Founded Year 2019
Location United States United States +1
Employees 5
Social

Get notified when SmartBreast Corp moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About SmartBreast Corp

SmartBreast empowers women with dense breasts to defeat cancer through early detection and treatment. 1 of every 2 Western women (2 of every 3 Asian women) have dense breasts, which is a normal condition. Until recently, most women were never told about their breast density and the facts that 1) dense breasts increase the risk for cancer up to 5 times and 2) screening mammography fails 70% of the time in dense breasts! Because dense tissue and cancer are both white on X-ray mammograms, cancer can easily be hidden until it is large and late-stage, when treatment is severe (mastectomy, radiation, chemotherapy, 29% survival after 5 years). When breast cancer is found early, survival is 99% after 5 years - the cancer is cured! SmartBreast offers one of the best methods to find early-stage cancer in dense breasts, called "Molecular Breast Imaging" or simply "MBI." MBI uses 3 innovations to solve the dense-breast problem: 1) MBI uses a tracer molecule (Nobel prize discovery) that concentrates in tumor cells, 2) MBI uses gamma photons that safely pass through dense breast tissue, and 3) MBI uses specially designed solid-state gamma cameras (based on another Nobel prize) to image the tracer concentrations in the breast. There is a bonus benefit to MBI: unlike mammography, MBI is painless, only mildly immobilizing the breast. We analyzed 24 publications (meta-analysis) to discover that the Cancer Detection Rate (CDR) for Digital Mammography (DM) is 4 cancers for every 1,000 dense-breast women screened. Digital Breast Tomosynthesis (DBT or 3D DM) finds 5 cancers; ultrasound (U/S) finds 7. Three modalities (MBI, Contrast-Enhanced Mammography (CEM), and MRI) each find 14 cancers. This means that DM misses 10 (71%), DBT misses 9 (61%) and U/S misses 7 (49%)! MBI is FDA-cleared and reimbursed in most locations, including 12 countries. SmartBreast manufactures, sells, installs, and services MBI. Write to [email protected] for more information.

No funding data available for SmartBreast Corp yet.

Get notified when SmartBreast Corp raises funding

FAQ About SmartBreast Corp

MBI Saves Lives through Early Cancer Detection in Dense Breasts
SmartBreast Corp was founded in 2019.
SmartBreast Corp is headquartered in United States.
SmartBreast Corp has approximately 5 employees.

We're actively collecting intelligence on SmartBreast Corp.

Track SmartBreast Corp to get notified

Don't just browse. Track.

Signal Tracker monitors SmartBreast Corp and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

One analytics cookie (Google Analytics). Cookie Policy